Invitrogen

MPZ Polyclonal Antibody

图: 1 / 4

MPZ Antibody (PA5-18773) in WB

Western blot analysis of MPZ using MPZ Polyclonal Antibody (Product # PA5-18773) (0.1 µg/mL) in staining of Rat Spinal Cord lysate (35 µg protein in RIPA buffer). Primary incubation was 1 hour. Detected by chemiluminescence.

Product Image Gallery

产品信息

PA5-18773

应用

建议稀释比

已发表文章

免疫印迹 (WB)

0.1-0.3 µg/mL

查看2篇已发表文章 2篇已发表文章

产品规格

种属反应

Rat

已发表种属

Human, Mouse, Rat

宿主/亚型

Goat / IgG

分类

Polyclonal

类型

Antibody

抗原

Synthetic peptide sequence (DHSRSTKAVSEK) corresponding to the internal amino acids of MPZ (aa 224-232).

查看免疫原

偶联物

Unconjugated Unconjugated Unconjugated

形式

Liquid

浓度

0.5 mg/mL

纯化类型

Ammonium sulfate precipitation

保存液

TBS, pH 7.3, with 0.5% BSA

内含物

0.02% sodium azide

保存条件

-20° C, Avoid Freeze/Thaw Cycles

运输条件

Wet ice

AB_10984960

产品详细信息

This antibody is predicted to react with canine, human and mouse based on sequence homology.

This antibody is tested in Peptide ELISA: antibody detection limit dilution 32,000.

靶标信息

Zero, also known as myelin protein zero (MPZ) is a Type 1 integral membrane glycoprotein that mediates adhesion of spiraling wraps of the myelin sheath in order to ensure stable synaptic transmission. Zero protein encompasses approximately 50% of total protein in the sheath scaffolding in contribution to structural integrity of peripheral myelin. Zero guides the compact myelin wrapping process through glycine zipper packing interface-dependent dimer and tetramer formation. Mutations (e.g. G134R) can abrogate multimer formation, cause demyelinating neuropathies, and are known to contribute to conditions that include Charcot-Marie-Tooth disease. Zero cytoplasmic domain undergoes serine and tyrosine phosphorylation, which appears to be prevalent during peak nerve myelination. Zero transcript is moderate in brain, abundant in thymus and most abundant in white matter of the CNS.

仅用于科研。不用于诊断过程。未经明确授权不得转售。

Product References

AAV2/9-mediated silencing of PMP22 prevents the development of pathological features in a rat model of Charcot-Marie-Tooth disease 1 A.

Nature communications

Gautier B,Hajjar H,Soares S,Berthelot J,Deck M,Abbou S,Campbell G,Ceprian M,Gonzalez S,Fovet CM,Schütza V,Jouvenel A,Rivat C,Zerah M,François V,Le Guiner C,Aubourg P,Fledrich R,Tricaud N

PA5-18773 was used in Western Blot to evaluate the safety and efficacy of recombinant adeno-associated viral vector serotype 9 (AAV2/9) expressing GFP and shRNAs targeting Pmp22 mRNA in animal models of Charcot-Marie-Tooth disease 1 A.

Wed Apr 21 00:00:00 UTC 2021

AAV2/9-mediated silencing of PMP22 prevents the development of pathological features in a rat model of Charcot-Marie-Tooth disease 1 A.

Nature communications

Gautier B,Hajjar H,Soares S,Berthelot J,Deck M,Abbou S,Campbell G,Ceprian M,Gonzalez S,Fovet CM,Schütza V,Jouvenel A,Rivat C,Zerah M,François V,Le Guiner C,Aubourg P,Fledrich R,Tricaud N

Wed Apr 21 00:00:00 UTC 2021

AAV2/9-mediated silencing of PMP22 prevents the development of pathological features in a rat model of Charcot-Marie-Tooth disease 1 A.

Nature communications

Gautier B,Hajjar H,Soares S,Berthelot J,Deck M,Abbou S,Campbell G,Ceprian M,Gonzalez S,Fovet CM,Schütza V,Jouvenel A,Rivat C,Zerah M,François V,Le Guiner C,Aubourg P,Fledrich R,Tricaud N